Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McPherson, E. A.
Right arrow Articles by Bagby, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McPherson, E. A.
Right arrow Articles by Bagby, S. P.
Related Collections
Right arrowRelated Article
J Am Soc Nephrol 15:493-500, 2004
© 2004 American Society of Nephrology


CLINICAL SCIENCE

Chymase-like Angiotensin II–Generating Activity in End-Stage Human Autosomal Dominant Polycystic Kidney Disease

Elizabeth A. McPherson*, Zaiming Luo*, Rachel A. Brown*, Linda S. LeBard*, Christopher C. Corless{dagger}, Robert C. Speth{ddagger} and Susan P. Bagby*

Departments of *Medicine and {dagger}Pathology, Oregon Health & Science University and Portland VA Medical Center, Portland, Oregon, and {ddagger}Department of Veterinary and Comparative Anatomy, Pharmacology and Physiology, Washington State University, Pullman, Washington.

Correspondence to: Dr. Susan P. Bagby, Division of Nephrology & Hypertension, Oregon Health and Science University, 3314 SW US Veterans Hospital Rd., Suite 262, Portland, OR 97239-2940. Phone: 503-494-8490; Fax: 503-494-5330; E-mail: bagbys{at}ohsu.edu

ABSTRACT. Autosomal dominant polycystic kidney disease (ADPKD) is characterized by exuberant inflammation and fibrosis, a process believed to contribute to progressive loss of normal renal function. Despite early-onset hypertension and intrarenal renin/angiotensin II (AngII) activation, angiotensin-converting enzyme (ACE) inhibition does not consistently confer renal protection in ADPKD. The hypothesis was that mast cells within the inflammatory interstitium release chymase, an enzyme capable of efficient conversion of AngI to AngII, providing an ACE-independent route of AngII generation. End-stage ADPKD renal tissue extracts and cyst fluids were assayed for time-dependent, chymostatin-inhibitable conversion of 125I-AngI to 125I-AngII under conditions of ACE and aminopeptidase inhibition by means of HPLC. Thirteen of 14 ADPKD kidney extracts exhibited chymase-like AngII-generating capacity; calculated initial reaction rates averaged 3.9 ± 2.9 fmol AngII/min/µg protein with a mean maximal conversion of 55% ± 30% of added substrate. AngII-generating activity was both protein and substrate dependent. All five cyst fluid samples were negative. Chymase-like activity was detectable in only three of six non-ADPKD kidney extracts. Immunoreactive chymase protein was present in/around mast cells within the fibrotic renal interstitium in all samples. Findings demonstrate for the first time the presence of mast cells, mast cell–associated immunoreactive chymase protein, and chymase-like AngII generating capacity in ADPKD cystic kidneys. Results support the potential for ACE-independent AngII generation and for mast cell–initiated inflammatory processes in ADPKD, each with therapeutic implications for ADPKD renal progression.


Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2004 15: A26-A29. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
S. R. Holdsworth and S. A. Summers
Role of Mast Cells in Progressive Renal Diseases
J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2254 - 2261.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
A. B. Chapman
Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1197 - 1204.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama
The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease
Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
C. R Lawson, T. W Doulton, and G. A MacGregor
Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 139 - 145.
[Abstract] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Loghman-Adham, C. E. Soto, T. Inagami, and L. Cassis
The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease
Am J Physiol Renal Physiol, October 1, 2004; 287(4): F775 - F788.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP